Mdm2 is a novel activator of ApoCIII promoter which is antagonized by p53 and SHP inhibition

Biochemical and Biophysical Research Communications

Volumn 417, Issue 2, 2012, Pages 744-746

  Yang, Zhihong ^a   Zhang, Yuxia ^a   Wang, Li ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Lipoprotein; Nuclear receptor; Oncogene; Promoter activity; Tumor suppressor

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN III; CELL NUCLEUS RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; PROTEIN MDM2; PROTEIN P53; SMALL HETERODIMER PARTNER NUCLEAR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; LIPOPROTEIN METABOLISM; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION;

APOLIPOPROTEIN C-III; HELA CELLS; HUMANS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855835029     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.027     Document Type: Article

References (14)

1. Kawakami A., Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J. Atheroscler. Thromb. 2009, 16:6-11.
2. Chen M., Breslow J.L., Li W., Leff T. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice correlation with changes in plasma triglyceride levels. J. Lipid Res. 1994, 35:1918-1924.
3. Staels B., Vu-Dac N., Kosykh V.A., Saladin R., Fruchart J.C., Dallongeville J., Auwerx J. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J. Clin. Invest. 1995, 95:705-712.
4. Hwang-Verslues W.W., Sladek F.M. Nuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter. Mol. Endocrinol. 2008, 22:78-90.
5. Y. Zhang, C.H. Hagedorn, L. Wang, Role of nuclear receptor SHP in metabolism and cancer. Biochim. Biophys. Acta.
6. Zhou T., Zhang Y., Macchiarulo A., Yang Z., Cellanetti M., Coto E., Xu P., Pellicciari R., Wang L. Novel polymorphisms of nuclear receptor SHP associated with functional and structural changes. J. Biol. Chem. 2010, 285:24871-24881.
7. Maeda Y., Seidel S.D., Wei G., Liu X., Sladek F.M. Repression of hepatocyte nuclear factor 4alpha tumor suppressor p53: involvement of the ligand-binding domain and histone deacetylase activity. Mol. Endocrinol. 2002, 16:402-410.
8. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387:296-299.
9. Guevara N.V., Kim H.S., Antonova E.I., Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat. Med. 1999, 5:335-339.
10. Lu X., Ma O., Nguyen T.A., Jones S.N., Oren M., Donehower L.A. The Wip1 phosphatase acts as a gatekeeper in the p53-Mdm2 autoregulatory loop. Cancer Cell 2007, 12:342-354.
11. Lucas B., Grigo K., Erdmann S., Lausen J., Klein-Hitpass L., Ryffel G.U. HNF4alpha reduces proliferation of kidney cells and affects genes deregulated in renal cell carcinoma. Oncogene 2005, 24:6418-6431.
12. Zhang Y., Wang L. Nuclear receptor SHP inhibition of Dnmt1 expression via ERRgamma. FEBS Lett. 2011, 585:1269-1275.
13. Maeda Y., Hwang-Verslues W.W., Wei G., Fukazawa T., Durbin M.L., Owen L.B., Liu X., Sladek F.M. Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene. Biochem. J. 2006, 400:303-313.
14. Neilsen P.M., Cheney K.M., Li C.W., Chen J.D., Cawrse J.E., Schulz R.B., Powell J.A., Kumar R., Callen D.F. Identification of ANKRD11 as a p53 coactivator. J. Cell Sci. 2008, 121:3541-3552.